Aaron Wealth Advisors’s PTC Therapeutics PTCT Stock Holding History

Aaron Wealth Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-422	Closed	-$15.7K	–	679
2022 Q1	$15.7K	Buy	+422	New	+$16.3K	﹤0.01%	698

Other funds holding PTCT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Aaron Wealth Advisors's PTCT Position: Q2 2022 in Review

Aaron Wealth Advisors sold out of PTC Therapeutics (PTCT) in Q2 2022, closing a stake of 422 shares — an estimated $15.7K sold.

Aaron Wealth Advisors first reported a position in PTCT in Q1 2022 and held it in 1 quarter. The position peaked at $15.7K in Q1 2022. 181 funds tracked by Wall St. Rank hold PTCT as of Q2 2022.

Aaron Wealth Advisors reported no remaining PTC Therapeutics position as of Q2 2022 after selling out during the quarter.
Aaron Wealth Advisors sold 422 PTC Therapeutics shares in Q2 2022, an estimated $15.7K.
Aaron Wealth Advisors first reported a position in PTC Therapeutics in Q1 2022 and held it in 1 quarter.
Aaron Wealth Advisors's PTC Therapeutics position peaked at $15.7K in Q1 2022.
181 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2022.

Based on Aaron Wealth Advisors's 13F filing for Q2 2022, filed 22 Jul 2022.